IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Cagle et al.

Group Art Unit: NYA

Serial No.:

10/705,441

Examiner:

02-12-04

NYA

Filed:

November 10, 2003

For:

Composition for Removing Human Ceruman

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Express Mail No. EV 224562690 US

Date: February 11, 2004

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby submits this statement. This submittal is made in accordance with 37 C.F.R. §§ 1.97 and 1.98 and § 609 of the Manual of Patent Examining Procedure.

The Examiner is respectfully requested to fully consider each of the references cited on the attached form PTO/SB/08 and, after such consideration, initial the enclosed Form PTO/SB/08 in the space provided next to each reference. Please return a copy of the initialed Form PTO/SB/08 with the next communication transmitted to the Applicant. Copies of all cited foreign patent documents and non-patent literature documents are enclosed. Copies of the cited U.S. patent documents are not enclosed. Any markings, underlines, notations or the like present in any reference are not to be construed as drawing the Examiner's attention to such marking or away from other portions of the reference.

PATENT APPLICATION

This statement is filed before the mailing of a first office action on the merits pursuant to 37 C.F.R. § 1.97(b), and therefore no fee for the consideration of this statement is enclosed herewith. However, the Commissioner is hereby authorized to charge any amount required for the consideration of this statement to Deposit Account No. 501051 of Alcon, Inc.

Respectfully submitted,

W. David Lee

Reg. No. 39,743

Alcon Research, Ltd. Mail Code Q-148 Fort Worth, TX 76134-2099

Tel: (817) 568-6029 Fax: (817) 551-4610

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known **Application Number** 10/705,441 11/10/03 Filing Date First Named Inventor Gerald Cagle Art Unit **Examiner Name** 2399 F US Attorney Docket Number

				U. S. PATENT D		
Examiner Initials*	Cite No. ¹	-	Document Number mber-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-	2,914,442	11/24/1959	Halpern	
	A2	US-	3,422,186	01/14/1969	Sasmor	
	A3	US-	4,556,554	12/03/1985	Calvo	
	A4	US-	4,559,322	12/17/1985	Maltz	
	A5	US-	4,769,171	09/06/1988	Harless	
	A6	US-	4,895,875	01/23/1990	Winston	
<u>-</u>	A7	US-	4,921,630	05/01/1990	Bhatia	
	A8	บร-	5,296,472	03/22/1994	Sanchez et al.	
	A9	US-	5,380,711	01/10/1995	Sanchez et al.	
	A10	US-	5,403,598	04/04/1995	Beck et al.	
	A11	US-	5,474,209	12/12/1995	Vallet Mas et al.	
	A12	US-	5,480,658	01/02/1996	Melman	
	A13	US-	5,604,190	02/18/1997	Chowhan et al.	
	A14	US-	5,782,345	07/21/1998	Guasch et al.	
	A15	US-	5,954,682	09/21/1999	Petrus	
	A16	US-	6,069,120	05/30/2000	Asgharian et al.	
	A17	US-	6,093,417	07/25/2000	Petrus	
	A18	US-	6,139,646	10/31/2000	Asgharian	
	A19	US-	6,228,323	05/08/2001	Asgharian et al.	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T 6
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	A20	GB 903,256	08/15/1962	Halpern		
	A21	EP 0 747 044	04/18/2001	Maugendre	Page 6	
	A22					<u></u>
	A23					_
	A24					<u>L</u>
	A25				İ	

<u></u>	
Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complet	te if Known	•
Application Number	10/705,441	
Filing Date	11/10/03	
First Named Inventor	Gerald Cagle	
Art Unit		
Examiner Name		
Attorney Docket Number	2399 F US	

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# knowledge)}	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1	^{US-} 6,309,596	10/33/2001	Xia et al.	
-	B2	US- 6,417,179	07/09/2002	Burkhart et al.	
	В3	US-			
	B4	US-			
	B5	US-			
	B6	US-			
	B7	US-			
	B8	US-			
		US-			

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
						<u> </u>
	1					

Examiner	Date	
Signature	Considered	
_		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCONDUCTOR O

DATE NAP	o for form 1449/PTC	,		Compl	ete if Known
17600SIDE	FORMATION DISCLOSUE		Application Number	10/705,441	
INFO	DRMATIO	N DIS	CLOSURE	Filing Date	11/10/03
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number Filing Date First Named Invent Art Unit Examiner Name	First Named Inventor	Gerald Cagle			
	Application Number 10/705,441 Filing Date 11/10/03 First Named Inventor Gerald Cagle Art Unit Examiner Name Attorney Docket Number 2300 5 US				
Sheet	3	of	4	Attorney Docket Number	2399 F US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	J. G. FRASER, "The efficacy of wax solvents: in vitro studies and a clinical trial." J. Laryngol. Otol., 1970, Vol. 84, pp. 1055-1064	
	C2	IMS Drug Monographs, File Drugmonog2, October 11, 2000, 5 pages.	
	СЗ	M. A. MANDOUR, ET AL., "Histological and histochemical study of the activity of ceruminous glands in normal and excessive was accumulation." pp. 1075-1085	
	C4	SHIGEKI SHICHIJO ET AL., "Carbohydrate Composition of Glycopeptides from the Human Cerumen." Biochemical Medicine 22, pp. 256-263 (1979)	
	C5	A. C. ROBINSON ET AL., "The efficacy of ceruminolytics: everything old is new again." The Journal of Otolaryngology 18:6, pp. 263-267, 1989	
	C6	JEFFREY WEINBERGER ET AL., "Steroid sulfatase activity in the skin of the external ear canal." The Journal of Otolaryngology 19:2, 1990, pp. 83-85	
	C7	BRIAN BINGHAM ET AL., "Cerumen: An Etymological and Historical Snippet." Journal of Otolaryngology 20:1, p. 65, 1991	
	C8	JERRY B. NAIBERG ET AL., "Swirls, wrinkles and the whole ball of wax (The source of keratin in cerumen)." The Journal of Otolaryngology 21:2, 1992, pp. 142-148	
	C9	ISABELLE OKUDA ET AL., "The organic composition of earwax." The Journal of Otolaryngology 20:3, 1991, pp. 212-215	
	C10	A. C. ROBINSON ET AL., "Impacted cerumen." The Journal of Otolaryngology, 19:2, 1990, pp. 86-90	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO ST& TRADENT

4

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

4

Comple	ete if Known	
Application Number	10/705,441	
Filing Date	11/10/03	
First Named Inventor	Gerald Cagle	_
Art Unit		
Examiner Name		
Attorney Docket Number	2399 F US	

NON PATENT LITERATURE DOCUMENTS				
	NON PATENT LITERATURE DOCUMENTS			
	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²		
D1				
D2				
D3				
D4				
D5	"Otocusi Enzimatico" Brochure from Laboratorios Cusi S-A. November, 1992. 3 pages			
D6	" Ear Preparations," "Ear Preparations of the British Pharmacopoeia," "Sodium Bicarbonate Ear Drops," and "Sodium Bicarbonate." British Pharmacopoeia 2000, 4 pages			
	D1 D2 D3 D4 D5	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. A. C. ROBINSON ET AL., "The mechanism of ceruminolysis." The Journal of Otolaryngology 18:6, 1989, pp. 268-273 EM KEANE ET AL., "Use of Solvents to Disperse Ear Wax." British Journal of Clinical Practice, Vol 49, No. 2, 1995, pp. 71-72 MAX KAMIEN, "Which cerumenolytic?" Australian Family Physician Vol. 28, No. 8, August 1999, pp. 817; 828 CHRISTOPHER DRIVER, "Removal of ear wax." Letters to the Editor, Australian Family Physician Vol. 28, No. 12, December 1999, p. 1215 "Otocusi Enzimatico" Brochure from Laboratorios Cusi S-A. November, 1992. 3 pages "Ear Preparations," "Ear Preparations of the British Pharmacopoeia," "Sodium Bicarbonate Ear		

Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.